IRCT20200624047908N1 IRCT 2020-07-05 Abadan University of Medical Sciences Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients DISCOVER Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients: a double-blind randomized clinical trial 2020-07-13 anticipated 1000 Complete https://irct.ir/trial/49198 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study will be a randomized, double-blind, phase 3, and multicenter clinical trials on 1000 patients. The randomization method is block randomization and the block size is 4. Sealed envelopes are used for the allocation concealment, Blinding description: In this study participants, researchers, Care providers, Data analyzers, and outcome assessors are blind. The medicine and placebo are similar in appearance, so patients do not understand which group they are in. 3 COVID-19. Intervention 1: Intervention group: Country Standard Pharmaceutical Protocol + SOF/DCV (400mg/60mg) one tablet daily for 10 days. Intervention 2: Control group: Country Standard Pharmaceutical Protocol + placebo one tablet daily for 10 days. Yes - There is a plan to make this available What will be shared: All data can be shared after the participants in the study are unrecognizable. When: The data access period after publishing of the article To whom: The data in this study will be available for researchers working in academic and scientific institutions, as well as the Food and Drug Administration. Conditions: Any analysis can be done by main researcher permission. Where to obtain: gholamali.eslami1351@gmail.com How to obtain: The researcher or pharmaceutical company can send their request to the academic email of project manager. After ensuring the accuracy of the submitted documents, the project manager will provide the requested information to the researcher or pharmaceutical company in of one week. Comments: